BEDFORD, Mass.--(BUSINESS WIRE)--May 1, 2017--
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will report first quarter 2017 financial results on
Friday, May 5, 2017. Following distribution of the earnings release via
wire services, the Ocular Therapeutix management team will host a live
conference call and webcast at 8:30 a.m. Eastern Time to review the
Company’s financial results and provide a general business update.
The live webcast can be accessed by visiting the Investors section of
the Company’s website at investors.ocutx.com. Please connect at least 15
minutes prior to the live webcast to ensure adequate time for any
software download that may be needed to access the webcast.
Alternatively, please call 844-464-3934 (U.S.) or 765-507-2620
(International) to listen to the live conference call. The conference ID
number for the live call will be 13632485. An archive of the webcast
will be available until May 19, 2017 on the Company’s website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development, manufacturing and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix’s lead product candidate,
DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use has
completed Phase 3 clinical development for the treatment of ocular pain
and inflammation following ophthalmic surgery. The FDA has accepted the
Company’s NDA resubmission for DEXTENZA for the treatment of ocular pain
following ophthalmic surgery and has established a target PDUFA date
of July 19, 2017. If approved, the Company will submit a supplement to
its NDA for ocular inflammation. OTX-TP (travoprost insert) is in Phase
3 clinical development for glaucoma and ocular hypertension. Ocular
Therapeutix is also evaluating injectable drug delivery depots for
back-of-the-eye diseases. Ocular Therapeutix's first product, the ReSure® Sealant,
is FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170501006159/en/
Source: Ocular Therapeutix, Inc.
Sandra Correa, 646-599-8637
and Business Group Director
Vice President of Marketing &
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
President, Investor Relations